<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676777</url>
  </required_header>
  <id_info>
    <org_study_id>SONIC</org_study_id>
    <nct_id>NCT03676777</nct_id>
  </id_info>
  <brief_title>Study Of Bacterial/Fungal Infections in Hospitalized Patients With Liver Cirrhosis in China</brief_title>
  <acronym>SONIC</acronym>
  <official_title>Prospective, Non-interventional, Multicenter Observational Study of Bacterial/Fungal Infections in Hospitalized Patients With Liver Cirrhosis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a national, investigator-initiated, multicenter, prospective, observational,
      web-based registry in hospitalized patients with cirrhosis across China.

      The overarching aim of this study is to investigate the epidemiology and clinical impact of
      bacterial/fungal infections in hospitalized patients with liver cirrhosis in China within the
      collaborative network. We also aimed to build up the national prospective cohort of
      hospitalized cirrhosis in China to stand in the future for the backbone of various research
      programs focused on infection, other complications of cirrhosis, organ failure, the ACLF
      syndrome, end-stage liver disease and beyond.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with cirrhosis are prone to infections due to the abnormal bacterial translocation
      and immune dysfunction. Infections are more common when these patients are admitted into the
      hospital. Infections are life-threatening complications of cirrhosis which can precipitate
      hepatic encephalopathy, acute kidney injury, and the acute-on-chronic liver failure (ACLF)
      syndrome. The survival rate is significantly decreased once infections set in, especially
      when the first-line empirical antibiotic therapy is insufficient or inappropriate. Moreover,
      the prevalence of multi-drug-resistant organism (MDRO) is naturally increasing across the
      world due to the overuse of antibiotics. Patients with cirrhosis, especially those at the
      decompensated stage are at high risk of developing MDRO due to recurrent hospitalizations and
      repeatedly exposed to antibiotics either for treatment or prophylactic purposes. Empiric
      antibiotic therapy could be very difficult without understanding the profile of antibiotic
      resistance and could be varied significantly among different areas.

      The issue of infection in patients with cirrhosis has been recently highlighted by
      International Club of Ascites with its &quot;GLOBAL&quot; study (ILC2018, GS-001) showing that the
      global prevalence of MDRO across the world was 34% (95% CI=31-37%). The prevalence of MDRO
      varies across the world with the highest in India followed by South America and other Asian
      countries. The source of acquisition (Community acquire, health-care related or nosocomial
      origin), site of infection (Spontaneous bacterial peritonitis, urinary tract, blood,
      respiratory tract, etc.) and category of the organism (Gram negative or positive) had an
      influence on the prevalence of MDRO and response to empirical antibiotic treatment. The
      results highlight the need to develop different empirical antibiotic strategies across
      different continents and countries, although China was not included in this study.
      Epidemiology data and investigation on the role of bacterial/fungal infection in patients
      with cirrhosis from China is therefore urgently needed.

      The overarching aim of this study is to investigate the epidemiology and clinical impact of
      bacterial/fungal infections in hospitalized patients with liver cirrhosis in China within the
      collaborative network. We also aimed to build up the national prospective cohort of
      hospitalized cirrhosis in China to stand in the future for the backbone of various research
      programs focused on infection, other complications of cirrhosis, organ failure, the ACLF
      syndrome, end-stage liver disease and beyond.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>28-day transplantation-free Survival</measure>
    <time_frame>From admission to 28-day post-admission</time_frame>
    <description>Survival at 28-day follow-up without liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristics of bacterial/fungal infection including the prevalence of infection, the source of acquisition, type of infection, multidrug resistance rate, antibiotic treatment efficiency and efficacy in relation to disease course and outcome</measure>
    <time_frame>From admission to discharge, an average of 28-day</time_frame>
    <description>Characteristics of bacterial/fungal infection including the prevalence of infection, the source of acquisition, type of infection, multidrug resistance rate, antibiotic treatment efficiency and efficacy in relation to disease course and outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between bacterial/fungal infection between other complications of cirrhosis、organ failure、AKI or ACLF.</measure>
    <time_frame>From admission to discharge, an average of 28-day</time_frame>
    <description>Association between bacterial/fungal infection between other complications of cirrhosis、organ failure、AKI or ACLF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in type of organ failure between bacterial/fungal infection and other precipitating events.</measure>
    <time_frame>From admission to discharge, an average of 28-day</time_frame>
    <description>Difference in type of organ failure between bacterial/fungal infection and other precipitating events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACLF and each sub-type organ failure development at 28-day</measure>
    <time_frame>From admission to discharge, an average of 28-day</time_frame>
    <description>ACLF defined as per EASL CLIF-C or NACSELD definition Organ failure defined as per CLIF-C OF criteria, including Liver, coagulation, kidney, brain, respiratory and circulatory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplantation-free Survival at 90-day</measure>
    <time_frame>From admission to 90 day post-admission</time_frame>
    <description>Survival at 90-day follow-up without liver transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 28-、90-day</measure>
    <time_frame>From admission to 90 day post-admission</time_frame>
    <description>Overall survival at 28-、90-day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission and further decompensations rate at 90-day post discharge</measure>
    <time_frame>From admission to 90 day post-discharge</time_frame>
    <description>Readmission and further decompensations rate at 90-day post discharge</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1232</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Infection</arm_group_label>
    <description>Patients admitted or developed bacterial/fungal infection while hospitalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-infection</arm_group_label>
    <description>Patients without bacterial/fungal infection</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum; Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients with cirrhosis evaluated in a dedicated and organized tertiary-care
        center (Liver Unit, Department of infectious diseases, Department of Gastroenterology,
        emergency department) across China.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient with cirrhosis as confirmed either by the histological scoring system,
             imaging technique (abdominal Ultrasound, CT or MRI), endoscopic findings or a
             combination of biochemical and clinical manifestation.

          -  Admitted for at least one of the following reasons:

               1. Bacterial infection/fungal infection

               2. Overt Ascites (Grade II-III)

               3. Gastrointestinal bleeding

               4. Hepatic encephalopathy

               5. Jaundice (Total bilirubin ≥5 mg/dL) with coagulation dysfunction (INR ≥1.5)

        Exclusion Criteria:

          -  1. Age below 16 or over 80 years

          -  2. Lactation/ Pregnancy women

          -  3. HIV infection

          -  4. Admitted for scheduled procedures (e.g., band ligation, splenectomy, transjugular
             intrahepatic portosystemic shunting, liver biopsy) or re-examination or
             multidisciplinary consultation)

          -  5. Hepatocellular carcinoma (HCC) outside Milan criteria or other disseminated
             malignancies

          -  6. Previous liver transplantation

          -  7. With previously known severe extra-hepatic diseases (e.g., chronic renal failure
             requiring hemodialysis, severe heart disease; severe chronic pulmonary disease,
             psychiatric disorders)

          -  8. Taking immunosuppressive or anticoagulation drugs for the treatment of
             extra-hepatic disease.

          -  9. Patient' s refusal to participation

          -  10. Failure to provide prior informed consent or with documented evidence that the
             patient has no legal surrogate decision maker and it appears unlikely that the patient
             will regain consciousness or sufficient ability to provide delayed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qing Xie, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qing Xie, M.D., Ph.D.</last_name>
    <phone>0086 13651804273</phone>
    <email>xieqingrjh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhujun Cao, M.D.</last_name>
    <phone>0086 15216652990</phone>
    <email>estherlucifer@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiabin Li, M.D., Ph.D.</last_name>
      <email>lijiabin@ahmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jiabin Li, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Critical Care Medicine of Liver Disease, Beijing You'an Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qinghua Meng, M.D.</last_name>
      <phone>0086 13601398756</phone>
      <email>wj5773@163.com</email>
    </contact>
    <investigator>
      <last_name>Qinghua Meng, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Hu, M.D., Ph.D.</last_name>
      <phone>0086 13608338064</phone>
      <email>hp_cq@163.com</email>
    </contact>
    <investigator>
      <last_name>Peng Hu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of severe Liver Diseases, Fuzhou Municipal Infectious Disease Hospital, Mengchao Hepatobiliary Hospital of Fujian Medical University,</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minghua Lin, M.D.</last_name>
      <phone>0086 13860691603</phone>
      <email>lmh543@163.com</email>
    </contact>
    <investigator>
      <last_name>Minghua Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiamen Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijuan Ouyang, M.D.</last_name>
      <phone>0086 13799768907</phone>
      <email>oyl_1105@163.com</email>
    </contact>
    <investigator>
      <last_name>Lijuan Ouyang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Disease, The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaorong Mao, M.D., Ph.D.</last_name>
      <phone>0086 13919157938</phone>
      <email>mxr2013@126.com</email>
    </contact>
    <investigator>
      <last_name>Xiaorong Mao, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Lanzhou City</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuerong Zhang, M.D.</last_name>
      <email>1583332518@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yuerong Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Guilin</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongchao Xian, M.D.</last_name>
      <phone>0086 18007736836</phone>
      <email>xianyongchao0901@163.com</email>
    </contact>
    <investigator>
      <last_name>Yongchao Xian, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Disease, The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minghua Su, M.D.</last_name>
      <phone>0086 15807719292</phone>
      <email>smh9292@163.com</email>
    </contact>
    <investigator>
      <last_name>Minghua Su, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Diseases, Third Affiliated Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caiyan Zhao, M.D., Ph.D.</last_name>
      <phone>0086 18533112898</phone>
      <email>zhaocy2005@163.com</email>
    </contact>
    <investigator>
      <last_name>Caiyan Zhao, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Liver Diseases, The Third People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Longgen Liu, M.D.</last_name>
      <phone>0086 13606140932</phone>
      <email>ssewllg@163.com</email>
    </contact>
    <investigator>
      <last_name>Longgen Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Diseases, the Fifth People's Hospital of Suzhou</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuanwu Zhu, M.D., Ph.D.</last_name>
      <phone>0086 13606202525</phone>
      <email>zhuchw@126.com</email>
    </contact>
    <investigator>
      <last_name>Chuanwu Zhu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihua Huang, M.D., Ph.D.</last_name>
      <phone>0086 13601513551</phone>
      <email>huanglihua1964@sina.com</email>
    </contact>
    <investigator>
      <last_name>Lihua Huang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Wu, M.D., Ph.D.</last_name>
      <phone>0086 13330122823</phone>
      <email>wuxiaoping2823@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoping Wu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoguang Dou, M.D.,Ph.D.</last_name>
      <phone>0086 18940251121</phone>
      <email>guang40@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoguang Dou, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cirrhosis, Institute of Liver Disease, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenghai Liu, M.D.,Ph.D.</last_name>
      <phone>021-20256666</phone>
      <email>chenghailiu@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Chenghai Liu, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongping Mu, M.D.,Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hepatology and Infection, Tongren Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Zhang, M.D.,Ph.D.</last_name>
      <phone>0086 13916348835</phone>
    </contact>
    <investigator>
      <last_name>Qin Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Xie, M.D., Ph.D.</last_name>
      <phone>0086 13651804273</phone>
      <email>xieqingrjh@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhujun Cao, M.D., Ph.D.</last_name>
      <phone>0086 15216652990</phone>
      <email>estherlucifer@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qing Xie, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhujun Cao, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University.</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingren Zhao, M.D., Ph.D.</last_name>
      <phone>0086 13509187086</phone>
      <email>zhaoyingren@mail.xjtu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yingren Zhao, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Diseases, Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongying Pan, M.D.</last_name>
      <phone>0086 13958020498</phone>
      <email>hypanhz@139.com</email>
    </contact>
    <investigator>
      <last_name>Hongying Pan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first Hospital of Jiaxing</name>
      <address>
        <city>Jiaxing</city>
        <state>Zhejiang</state>
        <zip>314000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingsheng Xie, M.D.,Ph.D.</last_name>
      <phone>0573-82082937</phone>
      <email>jxxxs2010@163.com</email>
    </contact>
    <investigator>
      <last_name>Xingsheng Xie, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Deng, M.D.,Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ningbo no.2 Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaoren Hu, M.D.</last_name>
      <phone>0086 13957881518</phone>
      <email>hu510@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Huadong Yan, M.D., Ph.D.</last_name>
      <phone>0086 13586579885</phone>
      <email>huadongy588@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yaoren Hu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huadong Yan, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting Hu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongping Chen, M.D.</last_name>
      <email>chenyongping@wmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yongping Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>November 17, 2019</last_update_submitted>
  <last_update_submitted_qc>November 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Qing XIe</investigator_full_name>
    <investigator_title>Head of the Department of Infectious diseases, Ruijin Hospital</investigator_title>
  </responsible_party>
  <keyword>Bacterial infection</keyword>
  <keyword>Fungal infection</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Multi-drug resistance</keyword>
  <keyword>Antibiotic treatment</keyword>
  <keyword>Clinical outcome</keyword>
  <keyword>Organ failure</keyword>
  <keyword>Acute-on-chronic liver failure</keyword>
  <keyword>Decompensated cirrhosis</keyword>
  <keyword>Complications of cirrhosis</keyword>
  <keyword>Acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

